European Archives - Page 790 of 1167 - European Medical Journal

Emobilisation for Optimum Uterine Fibroid Treatment

UTERINE FIBROIDS are non-cancerous growths that occur in the uterine muscular wall, and although they are benign and sometimes symptomless, they can cause…

EAU 2019 - Opening Ceremony

Our full congress review of EAU 2019 will be available soon for free in our Urology 7.1 eJournal, but here is a look at the opening ceremony while you wait..

An Interview with Kabir Nath from Otsuka

An interview with Kabir Nath, President and CEO, Otsuka North America at this year’s eyeforpharma, Barcelona conference. We speak to Kabir about Otsuka’s collaboration with Proteus Digital Health as well as the company’s unique set of values.

EAU 2019 - Interview - Prof Hendrik Van Poppel

An interview with Prof Hendrik Van Poppel, Chairman of the Scientific Committee of Europa Uomo, Board Member of European Cancer Organisation on…

The EMG 5th Annual Company Ball

Thursday 28th March saw the EMG team travel to Seckford Hall, Ipswich, for our quarterly planning session and the 5th annual company ball.

New Insights into Gestational Diabetes Management

A TEAM of researchers from Cardiff University, Cardiff, UK have found that mothers receiving insulin and/or metformin treatment during gestational..

Diabetes Treatment Could Play a Role in Protecting Against Alzheimer’s Disease

ALZHEIMER’S DISEASE could have a higher prevalence in patients who have untreated diabetes. Researchers from the University of Southern California..

‘Universal Health Coverage: Health for All’

Every year, World Health Day is celebrated on 7th April to mark the anniversary of the founding of World Health Organization (WHO) in 1948.

Combatting the Burden of Atrial Fibrillation

Atrial Fibrillation (AF) is the most common arrhythmia (irregular heart rhythm disorder), which is having a huge and increasing burden on patients…

“We all need a North Star: to keep us true, on track, inspired, and working tirelessly towards what we want to achieve”

Jennifer Turgiss leads the behaviour science and analytics teams at Johnson & Johnson (J&J), applying her expertise in behavioural and social science to develop digital health behaviour change interventions. We spoke to Jennifer at this year’s eyeforpharma, Barcelona on her long-standing career in the Health and Wellness industry and scaling bespoke patient behaviour change programmes.